Search Result

Pathways Recommended:	PI3K/Akt/mTOR Neuronal Signaling JAK/STAT Signaling

Results for "

Akt/mTOR signaling

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (26) mTOR (26) 5-HT Receptor (9) AMPK (3) Androgen Receptor (1) Antibiotic (2) Apoptosis (31) Autophagy (16) Bacterial (5) Bcl-2 Family (3) Caspase (4) CDK (1) COX (1) DNA/RNA Synthesis (1) Dopamine Receptor (3) EGFR (1) Endogenous Metabolite (1) ERK (1) FAK (3) Glutaminase (1) Hedgehog (2) HIF/HIF Prolyl-Hydroxylase (4) HSP (1) HSV (1) IGF-1R (1) Integrin (1) Interleukin Related (1) JNK (2) Keap1-Nrf2 (1) MDM-2/p53 (2) Microtubule/Tubulin (2) MMP (1) Necroptosis (1) NF-κB (5) NO Synthase (1) p38 MAPK (1) Parasite (3) PARP (2) PDK-1 (2) PI3K (17) Pim (1) PPAR (2) Prostaglandin Receptor (2) Reactive Oxygen Species (2) ROR (1) SphK (1) STAT (2) TNF Receptor (1) Topoisomerase (1) VEGFR (3) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (56) Cardiovascular Disease (5) Endocrinology (2) Infection (8) Inflammation/Immunology (8) Metabolic Disease (7) Neurological Disease (8)

By Targets:

Akt (26)

mTOR (26)

5-HT Receptor (9)

AMPK (3)

Androgen Receptor (1)

Antibiotic (2)

Apoptosis (31)

Autophagy (16)

Bacterial (5)

Bcl-2 Family (3)

Caspase (4)

CDK (1)

COX (1)

DNA/RNA Synthesis (1)

Dopamine Receptor (3)

EGFR (1)

Endogenous Metabolite (1)

ERK (1)

FAK (3)

Glutaminase (1)

Hedgehog (2)

HIF/HIF Prolyl-Hydroxylase (4)

HSP (1)

HSV (1)

IGF-1R (1)

Integrin (1)

Interleukin Related (1)

JNK (2)

Keap1-Nrf2 (1)

MDM-2/p53 (2)

Microtubule/Tubulin (2)

MMP (1)

Necroptosis (1)

NF-κB (5)

NO Synthase (1)

p38 MAPK (1)

Parasite (3)

PARP (2)

PDK-1 (2)

PI3K (17)

Pim (1)

PPAR (2)

Prostaglandin Receptor (2)

Reactive Oxygen Species (2)

ROR (1)

SphK (1)

STAT (2)

TNF Receptor (1)

Topoisomerase (1)

VEGFR (3)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (56)

Cardiovascular Disease (5)

Endocrinology (2)

Infection (8)

Inflammation/Immunology (8)

Metabolic Disease (7)

Neurological Disease (8)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Targets Recommended: Akt mTOR RGS Protein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-151622

PI3K/mTOR Inhibitor-11 1 Publications Verification	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-11 is an orally active *PI3K/mTOR* inhibitor (IC₅₀: 3.5, 4.6, and 21.3 nM for PI3Kα, PI3Kδ, and mTOR). PI3K/mTOR Inhibitor-11 regulates the PI3K/AKT/mTOR signaling pathway by inhibiting the phosphorylation of AKT and S6 proteins. PI3K/mTOR Inhibitor-11 can be used in the research of cancers .

HY-115449

Chromeceptin 94G6	IGF-1R Akt mTOR	Cancer
Chromeceptin (94G6) is an *IGF signaling* pathway** inhibitor. Chromeceptin suppresses IGF2 expression at mRNA and protein levels in hepatocyte and HCC cells. Chromeceptin inhibits the phosphorylation levels of AKT and mTOR .

HY-137996

Dehydrovomifoliol	Akt mTOR	Metabolic Disease
Dehydrovomifoliol is a *AKT/mTOR* dual inhibitor. Dehydrovomifoliol reduces lipid accumulation and lipogenesis by inhibiting the AKT/mTOR signaling pathway. Dehydrovomifoliol is used in nonalcoholic fatty liver disease research (NAFLD) .

HY-161857

Akt/mTOR-IN-1	Akt mTOR Caspase CDK	Cancer
Akt/mTOR-IN-1 (Compound 8r) is an *AKT/mTOR* signaling pathway inhibitor exhibiting an IC₅₀ value of 0.8 µM with anticancer activity. Akt/mTOR-IN-1 can decrease the expression of Caspase 3 and increase the expression of the autophagic protein Cyclin B1, thereby inducing cell autophagy and apoptosis. Akt/mTOR-IN-1 can be used in research related to non-small cell lung cancer (NSCLC) .

HY-119767

Jolkinolide A	VEGFR Apoptosis	Cancer
Jolkinolide A is a diterpenoid, can be extracted from the roots of Euphorbia fischeriana Steud. Jolkinolide A exhibits anti-tumor activity, by affecting on angiogenesis of tumor tissues. Jolkinolide A significantly inhibits the *Akt-STAT3-mTOR* signaling pathway and reduces the expression of VEGF in A549 cells .

HY-144059

AKT-IN-9	Akt	Cancer
AKT-IN-9 is a potent inhibitor of *AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR* signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-9 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 1) .

HY-144060

AKT-IN-10	Akt	Cancer
AKT-IN-10 is a potent inhibitor of *AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR* signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-10 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 4) .

HY-N1338

Royleanone NSC 122417	mTOR Akt	Cancer
Royleanone, a diterpenoid isolated from plants, inhibits the proliferation of cancer cells by inducing cell cycle arrest and mitochondria-mediated apoptosis, also inhibits cell migration potential, inhibits *mTOR/PI3/AKT* signaling pathway in LNCaP prostate cancer cells .

HY-169413

AKT-IN-25	Akt	Cancer
AKT-IN-25 (Compound 14a) is an inhibitor for *Akt, that inhibits the phosphorylation of Akt, and thereby inhibits the PI3K/Akt/mTOR* signaling pathway. AKT-IN-25 arrests the cell cycle at G1 phase, inhibits the cell migration of PANC-1, and inhibits the proliferation of cancer cells PANC-1, PATU-T, and SUIT-2 with IC₅₀s of 3.05, 1.32, and 3.85 μM, respectively .

HY-162141

MD102	Glutaminase Apoptosis	Cancer
MD102 is a potent TG2 inhibitor with an IC₅₀ value of 0.35 μM. MD102 stabilizes p53 by inhibiting TG2, inducing a decrease in p-AKT and p-mTOR downstream signaling, leading to tumor cell apoptosis .

HY-N0047

Polyphyllin I 1 Publications Verification	JNK mTOR Akt PDK-1 Autophagy Apoptosis	Cancer
Polyphyllin I is a bioactive constituent extracted from Paris polyphylla, has strong anti-tumor activity. Polyphyllin I is an activator of the JNK signaling pathway and is an inhibitor of *PDK1/Akt/mTOR* signaling. Polyphyllin I induces autophagy, G2/M phase arrest and apoptosis .

HY-N6843

Arnicolide D 1 Publications Verification	Caspase PI3K Akt mTOR STAT	Cancer
Arnicolide D is a sesquiterpene lactone isolated from Centipeda minima. Arnicolide D modulates the cell cycle, activates the caspase signaling pathway and inhibits the *PI3K/AKT/mTOR* and STAT3 signaling pathways. Arnicolide D inhibits Nasopharyngeal carcinoma (NPC) cell viability in a concentration- and time-dependent manner .

HY-N2602

Sanggenol L	MDM-2/p53	Cancer
Sanggenol L induces caspase-dependent and caspase-independent apoptosis in melanoma skin cancer cells . Sanggenol L induces of apoptosis via suppression of *PI3K/Akt/mTOR* signaling and cell cycle arrest via activation of p53 in p

HY-147613

PI3K/mTOR Inhibitor-6	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-6 (Compound 19c) is a potent and dual inhibitor of *PI3K/mTOR*. PI3K/mTOR Inhibitor-6 displays better stability in artificial gastric fluids than gedatolisib. PI3K/mTOR Inhibitor-6 significantly suppresses the PI3K/Akt/mTOR signaling pathway at 10 μM. PI3K/mTOR Inhibitor-6 has the potential for the research of cancer diseases .

HY-116191

WJD008	PI3K mTOR	Cancer
WJD008 is a potent dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor with antiproliferative and anticlonogenic activity in tumor cells and transformed cells with PIK3CA mutant. WJD008 inhibits kinase activity of PI3K α and *mTOR* and abrogates insulin-like growth factor-I-activated PI3K-Akt-mTOR signaling cascade. WJD008 is promising for research of cancers .

HY-N13176

Stellettin B	Autophagy Apoptosis PI3K Akt mTOR FAK	Cancer
Stellettin B is a triterpenoid compound that can be isolated from the marine sponge Jaspis stellifera. Stellettin B induces G1 phase arrest, apoptosis, and autophagy in human non-small cell lung cancer A549 cells by blocking the *PI3K/Akt/mTOR* pathway. Stellettin B can reduce the migration and invasion of liver cancer cells by decreasing the activation of the MAPK and *FAK/PI3K/AKT/mTOR* signaling pathways. Stellettin B can be used in the study of various tumors .

HY-18366A

RU-SKI 43 hydrochloride 2 Publications Verification	Hedgehog	Cancer
RU-SKI 43 hydrochloride is a potent and selective Hedgehog acyltransferase (Hhat) inhibitor with an IC₅₀ of 850 nM. RU-SKI 43 hydrochloride reduces Gli-1 activation through Smoothened-independent non-canonical signaling and decreases Akt and mTOR pathway activity. RU-SKI 43 hydrochloride has anti-cancer activity .

HY-N0279

Cardamonin Maximum Cited Publications 11 Publications Verification Cardamomin; Alpinetin chalcone	NF-κB STAT Wnt β-catenin Bcl-2 Family Apoptosis	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Cardamonin can be found from cardamom, and target various signaling molecules, transcriptional factors, cytokines and enzymes. Cardamonin can inhibit *mTOR, NF-κB, Akt, STAT3, Wnt/β-catenin* and COX-2. Cardamonin shows anticancer, anti-inflammatory, antimicrobial and antidiabetic activities .

HY-18366

RU-SKI 43	Hedgehog	Cancer
RU-SKI 43 is a potent and selective Hedgehog acyltransferase (Hhat) inhibitor with an IC₅₀ of 850 nM. RU-SKI 43 reduces Gli-1 activation through Smoothened-independent non-canonical signaling and decreases Akt and mTOR pathway activity. RU-SKI 43 has anti-cancer activity .

HY-146738

GSD-11	Akt	Cancer
GSD-11 is a potent and selective anti-austerity agent. GSD-11 inhibits the cell migration and colony formation of PANC-1 cells. GSD-11 inhibits the Akt/mTOR signaling pathway. GSD-11 has the potential for the research of pancreatic cancer[1].

HY-162143

SKI-349	SphK Akt mTOR	Cancer
SKI-349 is a dual-targeted inhibitor of sphingosine kinase 1/2 (SPHK1/2) and microtubule assembly (MDA). SKI-349 has anticancer activity. SKI-349 can inhibit the vitality, invasion, and AKT/mTOR signaling pathway of liver cells .

HY-P10323

T7 Peptide Tumstatin (74-98), human	Integrin FAK mTOR Apoptosis	Cancer
T7 peptide is an endothelial cell-specific inhibitor. T7 peptide interacts with αVβ3 integrin to inhibit the FAK, PI3-kinase, *PKB/Akt, and mTOR* signaling pathways in endothelial cells, ultimately suppressing protein synthesis and inducing apoptosis .

HY-N2590

Lupenone	Parasite PI3K Akt mTOR NF-κB	Infection Inflammation/Immunology Cancer
Lupenone is an orally active lupine-type triterpenoid that can be isolated from Musa basjoo. Lupenone Lupenone plays a role through the *PI3K/Akt/mTOR* and NF-κB signaling pathways. Lupenone has anti-inflammatory, antiviral, antidiabetic and anticancer activities .

HY-N6950

Hederacolchiside A1 1 Publications Verification	PI3K Akt mTOR Parasite Apoptosis	Infection Cancer
Hederacolchiside A1, isolated from Pulsatilla chinensis, suppresses proliferation of tumor cells by inducing apoptosis through modulating *PI3K/Akt/mTOR* signaling pathway . Hederacolchiside A1 has antischistosomal activity, affecting parasite viability both in vivo and in vitro .

HY-147614

PI3K/mTOR Inhibitor-7	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-7 (Compound 19i) is a potent and dual inhibitor of *PI3K/mTOR*. PI3K/mTOR Inhibitor-7 shows 4.7-fold higher potency than the positive control gedatolisib (0.3 vs. 1.4 μM, IC₅₀ values). PI3K/mTOR Inhibitor-7 significantly suppresses the PI3K/Akt/mTOR signaling pathway at 10 μM. PI3K/mTOR Inhibitor-7 has the potential for the research of cancer diseases .

HY-111137

Puquitinib XC-302 free base	Akt	Cancer
Puquitinib (XC-302 free base) is a multi-target inhibitor with the activity of inducing autophagy in nasopharyngeal carcinoma cells by inhibiting the PI3K/AKT/mTOR signaling pathway. Puquitinib was able to inhibit the proliferation of CNE-2 cells, showing a dose-dependent antiproliferative effect. Puquitinib induced the formation of autophagosomes and autolysosomes in CNE-2 cells, which were observed by fluorescence microscopy and electron microscopy. Puquitinib promoted the formation of LC3-II and increased the expression of beclin 1, while reducing the level of p62. Puquitinib inhibited the PI3K/AKT/mTOR pathway by reducing the expression of p-AKT and p-mTOR. Puquitinib also induced apoptosis in CNE-2 cells, and when autophagy was inhibited, the apoptosis rate was reduced, which means that autophagy may interact with apoptosis to induce cell death .

HY-N5136

25(R,S)-Ruscogenin	Apoptosis PI3K Akt mTOR	Cancer
Ruscogenin suppresses HCC metastasis by reducing the expression of MMP-2, MMP-9, uPA, VEGF and HIF-1α via regulating the *PI3K/Akt/mTOR* signaling pathway . And Ruscogenin alleviates LPS-induced pulmonary endothelial cell apoptosis by su

HY-N0047R

Polyphyllin I (Standard)	JNK mTOR Akt PDK-1 Autophagy Apoptosis	Cancer
Polyphyllin I (Standard) is the analytical standard of Polyphyllin I. This product is intended for research and analytical applications. Polyphyllin I is a bioactive constituent extracted from Paris polyphylla, has strong anti-tumor activity. Polyphyllin I is an activator of the JNK signaling pathway and is an inhibitor of PDK1/Akt/mTOR signaling. Polyphyllin I induces autophagy, G2/M phase arrest and apoptosis .

HY-128932

Cefminox sodium 1 Publications Verification MT-141	Bacterial PPAR Prostaglandin Receptor Antibiotic	Infection Cardiovascular Disease Endocrinology
Cefminox sodium (MT-141) is a semisynthetic cephamycin, which exhibits a broad spectrum of antibacterial activity . Cefminox sodium (MT-141) also acts as a dual agonist of prostacyclin receptor (IP) and PPARγ, upregulates cAMP production and PTEN expression and inhibits Akt/mTOR signaling. Cefminox sodium (MT-141) also prevents pulmonary arterial hypertension .

HY-N12124

Monascuspiloin Monascinol	Akt mTOR AMPK Androgen Receptor Apoptosis Autophagy	Cancer
Monascuspiloin (Monascinol) exhibits anti-androgenic activity with an IC₅₀ of 7 μM. Monascuspiloin inhibits viability of PC-3 and LNCaP with IC₅₀ of 45 and 47 μM. Monascuspiloin induces apoptosis in LNCaP through inhibition of *Akt/mTOR* signaling pathway, induces autophagy through activation AMPK signaling pathway and arrest cell cycle at G2/M phase in PC-3. Monascuspiloin exhibits antitumor efficacy in mice .

HY-125927

8-Aminoadenosine 1 Publications Verification 8-NH2-Ado	DNA/RNA Synthesis Akt mTOR Autophagy Apoptosis	Cancer
8-Aminoadenosine (8-NH2-Ado), a RNA-directed nucleoside analogue, reduces cellular ATP levels and inhibits mRNA synthesis. 8-Aminoadenosine blocks *Akt/mTOR* signaling and induces autophagy and apoptosis in a p53-independent manner. 8-Aminoadenosine has antitumor activity .

HY-155124

Antiproliferative agent-32	Apoptosis	Cancer
Antiproliferative agent-32 (Compound 1c) inhibits the phosphorylation of PI3K/Akt/mTOR signaling pathway. Antiproliferative agent-32 inhibits Huh7 and SK-Hep-1 cells proliferation, and induce cells apoptosis, causes mitochondrial damage. Antiproliferative agent-32 can be used for research of hepatocellular carcinoma .

HY-162382

KTC1101	PI3K Akt mTOR	Cancer
KTC1101 is an orally active pan-PI3K inhibitor. KTC1101 can inhibit the PI3K signaling pathway, reduce downstream *AKT* and *mTOR* phosphorylation, and reduces the expression of Ki67. The anti-tumor effect of KTC1101 has a dual mechanism of action: directly inhibiting tumor cell growth and dynamically enhancing immune response .

HY-B0965A

Thioridazine	Dopamine Receptor Apoptosis 5-HT Receptor Autophagy Bacterial	Neurological Disease Cancer
Thioridazine, an antagonist of the dopamine receptor D2 family proteins, exhibits potent anti-psychotic and anti-anxiety activities. Thioridazine is also a potent inhibitor of *PI3K-Akt-mTOR* signaling pathways with anti-angiogenic effect. Thioridazine shows antiproliferative and apoptosis induction effects in various types of cancer cells, with specificity on targeting cancer stem cells (CSCs) .

HY-146504

Topoisomerase I/II inhibitor 3	Topoisomerase PI3K Apoptosis Reactive Oxygen Species	Cancer
Topoisomerase I/II inhibitor 3 (compound 7) is a potent topoisomerase I (Topo I) and II (Topo II) dual inhibitor. Topoisomerase I/II inhibitor 3 can inhibit cell proliferation, invasion and migration, and induce apoptosis by inhibiting *PI3K*/Akt/mTOR signaling pathway. Topoisomerase I/II inhibitor 3 can be used for liver cancer research .

HY-B0965

Thioridazine hydrochloride 4 Publications Verification	Dopamine Receptor Apoptosis 5-HT Receptor Autophagy Bacterial	Infection Neurological Disease Cancer
Thioridazine hydrochloride, an orally active antagonist of the dopamine receptor D2 family proteins, exhibits potent anti-psychotic and anti-anxiety activities. Thioridazine hydrochloride is also a potent inhibitor of *PI3K-Akt-mTOR* signaling pathways with anti-angiogenic effect. Thioridazine hydrochloride shows antiproliferative and apoptosis induction effects in various types of cancer cells, with specificity on targeting cancer stem cells (CSCs) .

HY-128932R

Cefminox sodium (Standard)	Bacterial PPAR Prostaglandin Receptor Antibiotic	Infection Cardiovascular Disease Endocrinology
Cefminox (sodium) (Standard) is the analytical standard of Cefminox (sodium). This product is intended for research and analytical applications. Cefminox sodium (MT-141) is a semisynthetic cephamycin, which exhibits a broad spectrum of antibacterial activity . Cefminox sodium (MT-141) also acts as a dual agonist of prostacyclin receptor (IP) and PPARγ, upregulates cAMP production and PTEN expression and inhibits Akt/mTOR signaling. Cefminox sodium (MT-141) also prevents pulmonary arterial hypertension .

HY-N6950R

Hederacolchiside A1 (Standard)	PI3K Akt mTOR Parasite Apoptosis	Infection Cancer
Hederacolchiside A1 (Standard) is the analytical standard of Hederacolchiside A1. This product is intended for research and analytical applications. Hederacolchiside A1, isolated from Pulsatilla chinensis, suppresses proliferation of tumor cells by inducing apoptosis through modulating PI3K/Akt/mTOR signaling pathway . Hederacolchiside A1 has antischistosomal activity, affecting parasite viability both in vivo and in vitro .

HY-15672

FM19G11	HIF/HIF Prolyl-Hydroxylase	Neurological Disease Cancer
FM19G11 is a hypoxia-inducible factor-1-alpha (HIF-1α) inhibitor, and it inhibits hypoxia-induced luciferase activity with an IC₅₀ of 80 nM in HeLa cells. FM19G11 modulates other signaling pathways, including *mTOR* and PI3K/Akt/eNOS, when the HIF-1α pathway is inactivated under normoxic conditions .

HY-163538

TYM-3-98	PI3K Apoptosis	Cancer
TYM-3-98 is a selective inhibitor for PI3Kδ, with an IC₅₀ of 7.1 nM. TYM-3-98 inhibits proliferationso of B-lymphoma cells. TYM-3-98 inhibits PI3K/AKT/mTOR signaling pathway through induction of apoptosis. TYM-3-98 exhibits good pahrmacokinetic characters and antitumor efficacy in mouse/rat model, without significant toxicity .

HY-W016412

Coenzyme Q0 2 Publications Verification CoQ0	Apoptosis Autophagy EGFR Akt mTOR Caspase Bcl-2 Family Reactive Oxygen Species PARP COX NO Synthase TNF Receptor Interleukin Related MMP NF-κB	Neurological Disease Inflammation/Immunology Cancer
Coenzyme Q0 (CoQ0) is a potent, oral active ubiquinone compound can be derived from Antrodia cinnamomea. Coenzyme Q0 induces apoptosis and autophagy, suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of inflammation and redox imbalance. Coenzyme Q0 has anti-angiogenic activity through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling .

HY-N2447

Amarogentin 2 Publications Verification	AMPK Apoptosis	Metabolic Disease Cancer
Amarogentin is a secoiridoid glycoside that is mainly extracted from Swertia and Gentiana roots. Amarogentin exhibits many biological effects, including anti-oxidative, anti-tumour, and anti-diabetic activities. Amarogentin exerts hepatoprotective and immunomodulatory effects. Amarogentin promotes apoptosis, arrests G2/M cell cycle and downregulates of PI3K/Akt/mTOR signalling pathways. Amarogentin exerts beneficial vasculo-metabolic effect by activating AMPK .

HY-169100

Antiproliferative agent-57	VEGFR PI3K Akt mTOR p38 MAPK HIF/HIF Prolyl-Hydroxylase	Cancer
Antiproliferative agent-57 (compound M2) is a tumor angiogenesis inhibitor. Antiproliferative agent-57 inhibits the secretion of VEGF in SiHa cells under hypoxic conditions (IC₅₀=0.68 μM) without inducing cytotoxicity. Antiproliferative agent-57 can modulate the *PI3K/AKT/mTOR* and MAPK signaling pathways in tumor cells to inhibit the expression of HIF-1α and VEGF in tumor tissues .

HY-N0787

Cryptochlorogenic acid 1 Publications Verification 4-Caffeoylquinic acid; 4-O-Caffeoylquinic acid	Endogenous Metabolite NF-κB Keap1-Nrf2 mTOR HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
Cryptochlorogenic acid (4-Caffeoylquinic acid) is a naturally occurring phenolic acid compound with oral effectiveness, anti-inflammatory, antioxidant and anti-cardiac hypertrophy effects. Alleviating LPS (HY-D1056) and ISO (HY-B0468) by regulating proinflammatory factor expression, inhibiting NF-κB activity, promoting Nrf2 nuclear transfer, and regulating PI3Kα/Akt/ *mTOR* / HIF-1α signaling pathway Induced physiological stress response .

HY-B0965R

Thioridazine hydrochloride (Standard)	Dopamine Receptor Apoptosis 5-HT Receptor Autophagy Bacterial	Infection Neurological Disease Cancer
Thioridazine (hydrochloride) (Standard) is the analytical standard of Thioridazine (hydrochloride). This product is intended for research and analytical applications. Thioridazine hydrochloride, an orally active antagonist of the dopamine receptor D2 family proteins, exhibits potent anti-psychotic and anti-anxiety activities. Thioridazine hydrochloride is also a potent inhibitor of *PI3K-Akt-mTOR* signaling pathways with anti-angiogenic effect. Thioridazine hydrochloride shows antiproliferative and apoptosis induction effects in various types of cancer cells, with specificity on targeting cancer stem cells (CSCs) .

HY-14151

Prucalopride 2 Publications Verification	5-HT Receptor Apoptosis Autophagy	Neurological Disease Cancer
Prucalopride is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pK_is of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride also shows anticancer activity by blocking of the *PI3K/AKT/mTor* signaling pathway. Prucalopride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .

HY-148877

AT-533	HSP HSV HIF/HIF Prolyl-Hydroxylase VEGFR NF-κB ERK Akt FAK	Infection Inflammation/Immunology Cancer
AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including *Akt/mTOR/p70S6K, Erk1/2* and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs) .

HY-157169

IBL-302 AMU302	Pim mTOR Akt PI3K	Cancer
IBL-302 (AMU302) is an orally available dual-signaling inhibitor of PIM and PI3K/AKT/mTOR with activity against breast cancer and neuroblastoma. IBL-302 demonstrated in vivo efficacy in a nude mouse xenograft model, inhibiting trastuzumab (HY-P9907) resistance challenges. IBL-302 also enhances the effects of common cytotoxic chemotherapy drugs cisplatin (HY-17394), doxorubicin (HY-15142A), and etoposide (HY-13629) .

HY-14152

Prucalopride hydrochloride	5-HT Receptor	Cancer
Prucalopride hydrochloride is an orally active, selective and specific 5-HT4 receptor agonist (high affinity), with pK_is of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride hydrochloride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride hydrochloride also shows anticancer activity by blocking of the *PI3K/AKT/mTor* signaling pathway. Prucalopride hydrochloride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .

HY-N2447R

Amarogentin (Standard)	AMPK Apoptosis	Metabolic Disease Cancer
Amarogentin (Standard) is the analytical standard of Amarogentin. This product is intended for research and analytical applications. Amarogentin is a secoiridoid glycoside that is mainly extracted from Swertia and Gentiana roots. Amarogentin exhibits many biological effects, including anti-oxidative, anti-tumour, and anti-diabetic activities. Amarogentin exerts hepatoprotective and immunomodulatory effects. Amarogentin promotes apoptosis, arrests G2/M cell cycle and downregulates of PI3K/Akt/mTOR signalling pathways. Amarogentin exerts beneficial vasculo-metabolic effect by activating AMPK .

Cat. No.	Product Name

HY-L015

PI3K/Akt/mTOR Compound Library

643 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 643 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

HY-L074

Anti-Breast Cancer Compound Library

2,217 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 2,217 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

HY-L101

Anti-Liver Cancer Compound Library

2,053 compounds

Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.

Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc.

MCE offers a unique collection of 2,053 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-W016412

Coenzyme Q0

2 Publications Verification

CoQ0

Enzyme Substrates

Coenzyme Q0 (CoQ0) is a potent, oral active ubiquinone compound can be derived from Antrodia cinnamomea. Coenzyme Q0 induces apoptosis and autophagy, suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of inflammation and redox imbalance. Coenzyme Q0 has anti-angiogenic activity through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling .

Cat. No.	Product Name	Target	Research Area

HY-P10323

T7 Peptide Tumstatin (74-98), human	Integrin FAK mTOR Apoptosis	Cancer
T7 peptide is an endothelial cell-specific inhibitor. T7 peptide interacts with αVβ3 integrin to inhibit the FAK, PI3-kinase, *PKB/Akt, and mTOR* signaling pathways in endothelial cells, ultimately suppressing protein synthesis and inducing apoptosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks